More evidence backs insulin glargine safety

The cohort of around 55,000 patients from a US healthcare plan registry, comparing cancer incidence in patients receiving insulin glargine and human NPH, showed a hazard ratio of 1.2 for insulin glargine, indicating no increased risk of cancer.

There was no indication of an increased risk of breast cancer in women using insulin glargine or NPH for more than two years.

The results were consistent for prostate cancer, breast cancer and colon cancer, and for timing of insulin initiation,